We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search

Refine your search

Content type

Tags

Firm name

Author

548 results found

Article

LexOrbis | USA, India | 29 Jul 2019

Competitive generic therapy: Manna for generic companies

The US Food and Drug Administration (FDA) has over the years come up with initiatives to protect the interests of both the Patented and generic drug

Article

Windels Marx Lane & Mittendorf LLP | USA | 15 May 2019

Hatch-Waxman Team Wins Appeal for Dr. Reddy's Laboratories in esomeprazolenaproxen (Vimovo)

On Wednesday, May 15, a Windels Marx IP - Hatch-Waxman Act team achieved a significant victory on behalf of firm client Dr. Reddy’s Laboratories

Article

Windels Marx Lane & Mittendorf LLP | USA | 10 May 2019

Hatch-Waxman Team Wins a Motion For Judgment on the Pleadings for Slayback in Liquid Bendamustine (BELRAPZO)

On Thursday, May 9, a Windels Marx IP - Hatch-Waxman Act team achieved an important victory on behalf of firm client Slayback Pharma LLC (“Slayback”)

Article

Harness, Dickey & Pierce, PLC | USA | 23 Jan 2019

Secret Sales Can Qualify as Prior Art under the AIA

The America Invents Act (AIA) did not change the well-established meaning of “on sale” from the pre-AIA version of 35 U.S.C. 102. Helsinn Healthcare

Article

Finnegan, Henderson, Farabow, Garrett & Dunner LLP | USA | 31 Dec 2018

Preclinical Patent Considerations

All pharmaceutical companies, whether they are an innovator or a generic, must navigate the same complex legal and regulatory framework to bring a

Article

Banner Witcoff | USA | 21 Dec 2018

Endo v. Teva: Courts Continue to Invalidate Patent Claims Without Construing Them

Endo Pharmaceuticals Inc. and Mallinckrodt LLC sued for patent infringement against multiple defendants who had filed Abbreviated New Drug

Article

Banner Witcoff | USA | 21 Dec 2018

Endo v. Teva: Courts Continue to Invalidate Patent Claims Without Construing Them

Endo Pharmaceuticals Inc., and Mallinckrodt LLC sued for patent infringement against multiple defendants who had filed Abbreviated New Drug

Article

Harness, Dickey & Pierce, PLC | USA | 7 Dec 2018

Judicially Created Double Patenting Does Not Limit Statutory Patent Term Extension

In Novartis AG v. Ezra Ventures, LLC, 2017-2284 (December 7, 2018), the Federal Circuit affirmed the district court’s determination that

Article

Banner Witcoff | USA | 3 Dec 2018

Allergan v. Teva Pharmaceuticals USA: Will the Recognized Commercial Success of Restasis Demonstrate Non-Obviousness?

At the November 6, 2018, oral arguments at the U.S. Court of Appeals for the Federal Circuit, Allergan and the St. Regis Mohawk Tribe faced off

Article

Winston & Strawn LLP | USA | 2 Nov 2018

Acorda Therapeutics, Inc. v. Roxane Laboratories, Inc., Nos. 2017-2078 and 2017-2134 (Fed. Cir. Sep. 10, 2018)

The patentee sued the Abbreviated New Drug Application (ANDA) filers for infringement of patents covering its multiple sclerosis treatment, Ampyra

Previous page 1 2 3 ...